gsdmd n terminal Search Results


gsdmd n terminal  (MedChemExpress)
93
MedChemExpress gsdmd n terminal
Experimental validation <t>of</t> <t>CHP2</t> as a predictive biomarker for drug sensitivity and a driver of PANoptosis. ( A – C ) IC 50 growth inhibition curves of HCT116 and SW480 cells treated with first-line chemotherapeutic agents: ( A ) 5-fluorouracil (5-FU), ( B ) Oxaliplatin, and ( C ) Irinotecan. ( D , E ) IC50 curves for targeted agents: ( D ) Ribociclib and ( E ) Lapatinib. ( F ) Western blot analysis of key PANoptosis markers, including p-MLKL (necroptosis), <t>N-GSDMD</t> (pyroptosis), and Cleaved-Caspase 3 (apoptosis), in Control, CHP2-OV, and CHP2-OV-siRNA-3 groups. ( G – J ) Quantitative analysis of protein expression levels normalized to β-actin. Data are presented as mean ±SD from three independent experiments. * p < 0.05, ** p < 0.01.
Gsdmd N Terminal, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gsdmd+n+terminal/GSDMD+(N-terminal)+Antibody/pmc12985049-171-45-47
Average 93 stars, based on 1 article reviews
gsdmd n terminal - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
gasdermin d n terminal domain gsdmd n  (Wanleibio)
86
Wanleibio gasdermin d n terminal domain gsdmd n
(A) The change of mRNA expression levels in NLRP3, IL-1β and ASC in cardiac tissue (n = 6). (B) The change of protein expression levels in NLRP3, ASC, <t>GSDMD-N,</t> IL-1β, and caspase-1 p20 in cardiac tissue (n = 4), for each group. The obtained data were presented as the mean ± SD. CME, coronary microembolization; CME + VER, CME + Vericiguat; CME + VER + CC, CME + Vericiguat + AMPK inhibitor; AMPK, adenosine monophosphate-activated protein kinase; NLRP3, NOD-like receptor pyrin containing 3; IL-1β, interleukin-1 beta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *p < 0.05 vs . Sham group; **p < 0.05 vs . CME group; ***p < 0.05 vs. CME + VER group.
Gasdermin D N Terminal Domain Gsdmd N, supplied by Wanleibio, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gsdmd+n+terminal/anti+d+domain+gasdermin+gsdmd+n+n+terminal/pmc12576420-108-27-45
Average 86 stars, based on 1 article reviews
gasdermin d n terminal domain gsdmd n - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Experimental validation of CHP2 as a predictive biomarker for drug sensitivity and a driver of PANoptosis. ( A – C ) IC 50 growth inhibition curves of HCT116 and SW480 cells treated with first-line chemotherapeutic agents: ( A ) 5-fluorouracil (5-FU), ( B ) Oxaliplatin, and ( C ) Irinotecan. ( D , E ) IC50 curves for targeted agents: ( D ) Ribociclib and ( E ) Lapatinib. ( F ) Western blot analysis of key PANoptosis markers, including p-MLKL (necroptosis), N-GSDMD (pyroptosis), and Cleaved-Caspase 3 (apoptosis), in Control, CHP2-OV, and CHP2-OV-siRNA-3 groups. ( G – J ) Quantitative analysis of protein expression levels normalized to β-actin. Data are presented as mean ±SD from three independent experiments. * p < 0.05, ** p < 0.01.

Journal: Cells

Article Title: Machine Learning-Driven Multi-Omics Analysis Identifies CHP2 as a Key PANoptosis-Related Dual-Function Biomarker in Colorectal Cancer

doi: 10.3390/cells15050430

Figure Lengend Snippet: Experimental validation of CHP2 as a predictive biomarker for drug sensitivity and a driver of PANoptosis. ( A – C ) IC 50 growth inhibition curves of HCT116 and SW480 cells treated with first-line chemotherapeutic agents: ( A ) 5-fluorouracil (5-FU), ( B ) Oxaliplatin, and ( C ) Irinotecan. ( D , E ) IC50 curves for targeted agents: ( D ) Ribociclib and ( E ) Lapatinib. ( F ) Western blot analysis of key PANoptosis markers, including p-MLKL (necroptosis), N-GSDMD (pyroptosis), and Cleaved-Caspase 3 (apoptosis), in Control, CHP2-OV, and CHP2-OV-siRNA-3 groups. ( G – J ) Quantitative analysis of protein expression levels normalized to β-actin. Data are presented as mean ±SD from three independent experiments. * p < 0.05, ** p < 0.01.

Article Snippet: After the protein concentration was determined with a BCA protein assay kit (Beyotime, P0010), identical amounts of proteins were subjected to SDS-PAGE and transferred onto PVDF membranes, which were subsequently incubated with primary antibodies against CHP2 (Boster, Wuhan, China, A08478-2, 1:1000), p-MLKL (MCE, HY86069, 1:1000), GSDMD (N-terminal) (MCE, HY- P85810 , 1:1000), Cleaved Caspase-3 (HY- P86370 ) and β-actin (Servicebio, ZB15001-HRP, 1:2000).

Techniques: Biomarker Discovery, Inhibition, Western Blot, Control, Expressing

(A) The change of mRNA expression levels in NLRP3, IL-1β and ASC in cardiac tissue (n = 6). (B) The change of protein expression levels in NLRP3, ASC, GSDMD-N, IL-1β, and caspase-1 p20 in cardiac tissue (n = 4), for each group. The obtained data were presented as the mean ± SD. CME, coronary microembolization; CME + VER, CME + Vericiguat; CME + VER + CC, CME + Vericiguat + AMPK inhibitor; AMPK, adenosine monophosphate-activated protein kinase; NLRP3, NOD-like receptor pyrin containing 3; IL-1β, interleukin-1 beta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *p < 0.05 vs . Sham group; **p < 0.05 vs . CME group; ***p < 0.05 vs. CME + VER group.

Journal: The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology

Article Title: Vericiguat reduces pyroptosis in rats with coronary microembolization by inhibiting the AMPK/Nrf2/NLRP3 signaling pathway

doi: 10.4196/kjpp.25.008

Figure Lengend Snippet: (A) The change of mRNA expression levels in NLRP3, IL-1β and ASC in cardiac tissue (n = 6). (B) The change of protein expression levels in NLRP3, ASC, GSDMD-N, IL-1β, and caspase-1 p20 in cardiac tissue (n = 4), for each group. The obtained data were presented as the mean ± SD. CME, coronary microembolization; CME + VER, CME + Vericiguat; CME + VER + CC, CME + Vericiguat + AMPK inhibitor; AMPK, adenosine monophosphate-activated protein kinase; NLRP3, NOD-like receptor pyrin containing 3; IL-1β, interleukin-1 beta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *p < 0.05 vs . Sham group; **p < 0.05 vs . CME group; ***p < 0.05 vs. CME + VER group.

Article Snippet: Following the blocking step with 5% skim milk for one hour, the membranes were then left to incubate overnight at 4°C with primary antibodies specific to NLRP3, gasdermin D-N-terminal domain (GSDMD-N), cleaved caspase-1 p20, ASC, IL-1β, GAPDH, p-AMPK, AMPK and Nrf2 (all antibodies sourced from Wanleibio, 1:1,000).

Techniques: Expressing